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The term cholestasis is Greek in origin, meaning bile stoppage. In its most 
overt form, cholestasis presents to the clinician as jaundice. However, jaundice 
is only the tip of the iceberg of cholestatic liver disease.
The incidence of neonatal cholestasis is estimated around 1 in 2500 live births. 
Cholestasis must always be considered in newborns with prolonged jaundice 
lasting more than 14-21 days. There are a number of contributing factors for 
neonatal cholestasis which include bile duct abnormalities; infections, such as 
sepsis and urinary tract infections; inherited and metabolic disorders; endocrine 
disorders; chromosomal disorders; toxicity from parenteral nutrition; vascular 
disorders; prematurity, lack of enteral feedings and medications. The most 
common causes of neonatal cholestasis are biliary atresia and idiopathic 
neonatal hepatitis.
the aim : of this review is to discuss the pathophysiology, causes and approach 
of cholestasis.




Neonatal jaundice, neonatal hyper-
bilirubinemia, cholestatic liver disease, 
biliary atresia, metabolic causes of 
jaundice.
DeFiNitiON                                       
Neonatal cholestasis is defined as im-
paired bile formation or bile flow result-
ing in accumulation of biliary substanc-
es (bilirubin, bile acids and cholesterol) 
in blood and extrahepatic tissues. This 
can occur anywhere between the sinu-
soidal membrane of the hepatocyte and 
the ampulla of vater.
It is generally associated with a mea-
sured conjugated (direct-acting) biliru-
bin fraction of greater than 2 mg/dl or 
more than 20% of the total bilirubin.1
PatHOPHYSiOlOGY                          
The normal process of bile production 
involves two main processes: uptake of 
bile acids by hepatocytes from the blood 
and excretion of bile acids into the bil-
iary canaliculus. Uptake of bile acids 
from sinusoidal blood is an active pro-
cess at the sinusoidal membrane of the 
hepatocytes2. Na taurocholate co trans-
porting polypeptide (NTCP) and organic 
anion transporting proteins (OATP) are 
the two main receptors involved in the 
uptake of conjugated bile acids by the 
liver cells. These receptors are also re-
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sponsible for the transport of other an-
ions like drugs and toxins through the 
hepatocellular membrane.
At the canalicular membrane, bile salt 
export pump (BSEP) and the multidrug 
resistant proteins MRP2 and MDR3 are 
involved in the secretion of bile acids 
into bile (Figure 1). 
Fig. 1: Role of hepatic transporters in the 
formation of bile.3                
Genetic defects in different transporters 
are recognized as the cause of a wide 
range of familial childhood cholestatic 
diseases, e.g. mutations in the gene for 
BSEP cause progressive familial intra-
hepatic cholestasis (PFIC) type 2. More 
surprisingly, is the recognition of the 
importance of mutations in transporters 
causing adult onset diseases such as in-
trahepatic cholestasis of pregnancy as it 
is associated in some cases with muta-
tions in the gene for MDR3.3
Bile flow is low in the fetus and new-
born as a result of a combination of im-
mature bile acid synthetic and transport 
processes. The dynamics of the devel-
opment process for human hepatocyte 
transporters have not yet been quanti-
fied, but plasma bile acids do not fall 
into the normal adult range until 6 
months of age.4
cliNical  PReSeNtatiON             
This presentation is usually with pro-
longed jaundice. Newborn infants have 
pale stools and a history of persistently 
dark yellow urine confirms the presence 
of conjugated hyperbilirubinemia. The 
presence of pale stools is very sensitive 
for liver disease and even as an iso-
lated finding should prompt immediate 
investigation. Acholic or white stools 
imply complete cholestasis with a con-
sequently worse prognosis.
An alternative presentation is with 
bleeding due to vitamin K deficiency, as 
bruising, or with a devastating intracra-
nial bleeding. Seizures may result from 
hypocalcaemia secondary to vitamin D 
deficiency or rarely due to hypoglyce-
mia, the latter strongly suggests meta-
bolic liver disease or hypopituitarism.5
Examination reveals hepatomegaly in 
most cases and splenomegaly in 50% 
of cases. Other helpful diagnostic clini-
cal features may include stigmata of 
syndromic disorders, facial dysmor-
phic features, and evidence of congeni-
tal heart disease and manifestations of 
intra-uterine infection such as growth 
retardation or thrombocytopenia. Cuta-
neous cavernous haemangiomata may 




table 1 : Differential diagnosis  of neonatal cholestasis.6
         Classification                                 Example
I. Bile duct obstruction:
          -  Extrahepatic disorders             - Biliary atresia, choledochal cysts, spontaneous
                                                                perforation of common bile duct,  Caroli's disease, 
                                                                bile duct stenosis, cholelithiasis, tumors/masses 
                                                                (intrinsic and extrinsic).
          - Intrahepatic disorders               - Alagille's syndrome, nonsyndromic paucity of 
                                                                 intrahepatic ducts, neonatal sclerosing cholangitis,
                                                                congenital hepatic  fibrosis, inspissated bile/mucous plug
ii. Neonatal Hepatitis:
          - Viral                                          - Cytomegalovirus, herpes (simplex, zoster, human type 6),
                                                                rubella, reovirus type 3, adenovirus, enteroviruses,
                                                                parvovirus B19, hepatitis B, HIV
           - Bacterial and parasitic.              Bacterial sepsis, UTI , listeriosis, tuberculosis,   toxoplasmosis.
          - Idiopathic neonatal hepatitis
III. Cholestatic syndromes :               
       - Progressive familial intrahepatic           caused by transport defect                       
          Cholestasis (PFIC)                                type 1 (Bylers disease, defect in FIC1, a P-type ATPase),
                                                                        type 2 (defect in BSEP, canalicular bile acid pump),
                                                                        type 3 (defect in MDR-3, a canalicular phospholipids transporter)
       - Hereditary cholestasis with 
          Lymphedema (Aagenaes syndrome)
        - Benign recurrent cholestasis (BRIC)
       -  Dubin-Johnson syndrome
       -  Rotor syndrome
IV. Metabolic disorders:
     - ∞1-Antitrypsin deficiency
     - Cystic fibrosis
     - Neonatal iron storage disease
     - Amino acid disorders                     - Tyrosinemia, hypermethionemia, mevalonate kinase
                                                                  deficiency
     - Lipid disorders                               - Niemann Pick disease, Gaucher's disease, Wolman's 
                                                                Disease. 
     -Urea cycle disorders                       - Arginase deficiency
    - Carbohydrate disorders                  - Galactosemia, fructosemia, glycogen storage disease type IV.
 
    -Mitochondrial disorders
     - Peroxisomal disorders                  - Zellweger syndrome, infantile Refsum's disease,
                                                                other enzymopathies
     - Bile acid synthetic defects           - 3b-Hydroxy-D5-C27-steroid dehydrogenase 
                                                                 isomerase, D4-3-oxosteroid 5b-reductase,
                                                                 oxysterol 7 ∞-hyroxylase
 V.  Endocrinopathies :                          - Hypopituitarism (septooptic dysplasia),
                                                                 -Hypothyroidism.
VI. Toxic :                                              - Drugs, parenteral nutrition,
VII. Miscellaneous Associations:         Shock/hypoperfusion, histiocytosis X, neonatal lupus 
                                                                erythematosus, Indian childhood cirrhosis, autosomal 
                                                                trisomies, graft-versus-host disease, erythrophagocytic
                                                                lymphohistiocytosis, extracorporeal membrane-oxygenation,
                                                                venoocclusive disease.
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evalUatiON OF cHOleStaSiS     
Any infant presenting with jaundice 
beyond 2 weeks after birth should be 
immediately evaluated for cholestasis. 
A detailed history (including family 
history, pregnancy and delivery history 
and postnatal course) and physical ex-
amination could provide clues to a spe-
cific diagnosis.7
Once cholestasis is established, further 
investigations should be done in a step-
wise manner to establish the specific 
cause of cholestasis (Figure 2). The in-
vestigations should first rule out condi-
tions requiring immediate intervention 
like sepsis, metabolic disorders like 
galactosemia, glycogen storage disor-
ders and other endocrinopathies. The 
next step is to look for biliary atresia. 
It is important to establish or rule out 
biliary atresia early because of better 
prognosis if the patient undergoes sur-
gical intervention before 60 days of life. 
Then further investigations should be 
done to establish the cause of intrahe-
patic cholestasis (Table 1). The poten-
tially extensive evaluation of an infant 
with cholestasis (Figure 2 and Table 1) 
should be individualized to efficiently 
and promptly establish a diagnosis.8 
Fig. 2 : An approach to  infant with Cholestasis.8
139
Amel Elfaramawy
SPeciFic DiSeaSeS                            
Extrahepatic biliary atresia:
Biliary atresia is an idiopathic inflam-
matory process involving the bile ducts 
resulting in obstruction of the biliary 
tract, chronic cholestasis and progres-
sive fibrosis and eventually leads to 
biliary cirrhosis. It accounts for ap-
proximately one-third of the cases of 
neonatal cholestasis and is the most 
common cause of liver transplantation 
in children.9
The incidence of biliary atresia has 
been estimated to be about 1:15,000. It 
is worldwide in distribution and occurs 
in all races, though more commonly 
in nonwhites. The etiology of biliary 
atresia is still unclear. Various studies 
have suggested a possible relationship 
between biliary atresia and viral infec-
tions like reovirus 3, rotavirus C and 
cytomegalovirus but this has not been 
conclusively proven. Increased risk of 
biliary atresia in family members of an 
affected individual has been noted and 
may suggest genetic etiology. Studies 
have shown that severe jaundice and 
death within 1 week of life occurs in the 
inv mouse, a transgenic mouse with de-
letion of the inversin gene and is asso-
ciated with biliary atresia and complete 
abdominal situs inversus.10
There are two forms of biliary atresia: 
1- Isolated biliary atresia, the more 
common form, also known as peri- or 
postnatal form.
2- biliary atresia associated with situs 
inversus and polysplenia syndrome, also 
known as the fetal or embryonic form. 
The polysplenia syndrome includes si-
tus inversus, poly- or asplenia, cardio-
vascular malformations and anomalies 
of the portal vein and hepatic artery.11
Clinically, babies usually present with 
cholestasis 2-3 weeks after birth, and 
their birth weight is appropriate for 
ges tation age, hepatomegaly is usu-
ally found on clin ical examination. The 
stool is clay color and pruritus is rare 
before 5 months of age. Laboratory in-
vestigations usually show raised total 
and direct serum bilirubin, serum ami-
notransferases, alkaline phosphatase 
and gamma-glutamyl transpep tidase 
(GGT). Liver histopathology shows 
bile duct pro liferation, bile lakes, cellu-
lar infiltrate, and fibrous tissue.12
T99c-labelled compounds of Imino-
diacetic acid (e.g. HIDA) are simple 
ways of show ing bile duct patency in 
suspected biliary atresia. Abdominal ul-
trasound occasionally shows triangular 
cord sign (TC sign), if the gallbladder 
is unidentified by ultrasound this may 
indicate obliteration of its lumen. Both 
percutaneous liver biopsy and percuta-
neous cholan giography support a diag-
nosis of biliary atresia. In most cases of 
biliary atresia, exploratory laparotomy 
is help ful in confirming the diagnosis.
Early biliary atresia requires Kasai por-
toenterostomy around 6 weeks of age. 
Post operative cholangitis is a well 
recognized complication of Kasai op-
eration and usually it is treated with 
ampicillin and an aminoglycoside with 
or without clindamycin.  Other com-
plications include portal hypertension 
and fat soluble vitamin malabsorption 
which respond to fat soluble vitamin 
supplement.  Liver transplantation can 
be life saving and should be done be-
fore the onset of irreversible hepatic 
decompensation.12
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Another cause of extra hepatic cholesta-
sis in infancy is choledochal cyst which 
is diagnosed by abdominal ultrasound 
and once the diagnosis is confirmed, 
surgical excision is the best therapy. 
Fig. 2: US showing Choledocal cyst.
Idiopathic Neonatal Hepatitis
Idiopathic neonatal hepatitis, also 
known as giant cell hepatitis, accounts 
for approximately one-third of the cases 
of neonatal cholestasis. It is diagnosed 
by the presence of the classic patho-
logical findings and the absence of any 
identifiable cause of cholestasis. There 
are two different categories: Sporadic 
cases and familial cases that could 
likely suggest an undiagnosed genetic 
or metabolic disease. These infants usu-
ally have low birth weight.  
Jaundice is present within the first week 
of life. Acholic stools are usually absent 
unless there is severe cholestasis. On 
physical examination, liver is enlarged 
and firm in consistency. Serum bilirubin 
and transaminases are mildly elevated. 
Liver biopsy usually shows lobular 
disarray with hepatocellular swelling 
(ballooning), focal hepatic necrosis and 
giant cell transformation. Management 
is usually supportive with nutritional 
support, vitamin supplementation and 
treatment of complications of cholesta-
sis. Prognosis is variable with sporadic 
cases having very good prognosis with 
90% resolution by age 1 year and rela-
tively poor prognosis in familial cases 
suggesting some inborn errors.13
Metabolic and Genetic Causes of 
Neonatal cholestasis
Metabolic disorders present with a 
wide variety of clinical manifestations 
depending on the nature of underlying 
defect.
Recent progress in liver cell biology 
and molecular genetics has dramatically 
changed our understanding of the mo-
lecular pathogenesis of congenital and 
familial cholestatic diseases. The con-
cept that familial cholestatic disorders 
are caused by mutations in genes cod-
ing for hepatobiliary transport proteins 
has nicely bridged basic and clinical 
medicine and will soon have an impact 
on our current diagnostic and clinical 
practice.14
Table (2) summarizes the metabolic and 
genetic causes of neonatal cholestasis, 
some of them will be discussed.
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table 2: Metabolic and Genetic Causes of Neonatal Cholestasis.15
Disease     inborn error r Hepatic pathology Diagnostic studies
Galactosemia Galactose-1-phosphate 
uridylyltransferase 




uridylyltransferase  assay of red 
blood cells
Fructosemia Fructose-1-phosphate  




aldolase assay or leukocyte DNA 
analysis
Tyrosinemia Fumarylacetoacetase 
deficiency    
Necrosis, steatosis, 
pseudoacini, portal fibrosis 
Urinary succinylacetone, 
fumarylacetoacetase assay of 
RBCs




proliferation, bile duct mucus, 
portal fibrosis
Sweat test and leukocyte DNA 
analysis
Hypopituitarism Deficient production of 
pituitary hormones
Cholestasis, giant cells Thyroxine, thyroid-stimulating 
hormone cortisol levels
∞1-Antitrypsin 
deficiency   
∞1-Antitrypsin gene 
mutation (PiZZ  phenotype)    




PAS diastase- resistant cytoplasmic 
granules                                    
Gaucher’s disease  b-Glucosidase deficiency Cholestasis, HSM ytoplasmic 
inclusions Kupffer cells (foam 
cells)
b-Glucosidase assay in leukocytes 
Niemann-Pick disease Lysosomal sphingomyelinase 
deficiency
Cholestasis, cytoplasmic 
inclusions in Kupffer cells 
& HSM
Sphingomyelinase assay of 
leukocytes or liver or fibroblasts 
(type C); leukocyte DNA analysis




Fibrosis, cirrhosis, PAS 
diastase-resistant cytoplasmic 
inclusions        
Branching enzyme analysis of 
leukocytes or Liver
Neonatal iron storage 
disease
Unknown Giant cells, portal fibrosis 
cirrhosis , hemosiderosis,







Cholestasis, necrosis fibrosis, 
cirrhosis, 
Plasma very-long-chain fatty acids, 
qualitative bile acids, pipecolic 
acid,liver electron microscopy
Abnormalities in bile 
acid metabolism 
Several enzyme deficiencies 
defined 
Cholestasis, necrosis, giant 
cells 
Urine, serum duodenal fluid 
analyzed for bile acids by 
fast-atom bombardment mass 
spectroscopy
PFIC types 1 and 2         FIC1 and BSEP gene 
mutations
Cholestasis, necrosis, giant 
cells, fibrosis (pericentral) 
Histology, family history low or 
normal GGT normal cholesterol 
DNA analysis
PFIC type 3 MDR-3 gene mutations Cholestasis, bile duct 
proliferation, Portal fibrosis
Bile phospholipid level DNA 
analysis
Alagille’s syndrome 
(syndromic paucity, of 
interlobular bile ducts)
Jagged 1 gene mutations  Cholestasis paucity of 
interlobular bile, ducts, 
increased copper levels,
Three or more clinical features 
liver histology DNA analysis
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∞ 1-Antitrypsin Deficiency (∞ 1-AT):
This is the most common inherited 
cause of neonatal cholestasis.
 ∞1-AT is a protease inhibitor produced 
in the liver. The deficiency is caused by 
mutations in the gene found on chromo-
some 14. More than 75 different phe-
notypes of ∞1-AT are named according 
to migration characteristics on poly-
acrylamide gels, based on differences 
in isoelectric point (Pi), with M normal 
and Z most deficient. The incidence of 
homozygous PiZZ that is associated 
with neonatal liver disease and adult 
emphysema is 1 in 2000 live births in 
European and North American popula-
tions. Only 15% of PiZZ neonates de-
velop clinical disease within the next 20 
years. The mechanism of liver disease 
is accumulation of the defective mol-
ecule in the liver.
Clinical presentation is very similar to 
biliary atresia. These infants also have 
intrauterine growth retardation and are 
more likely to develop coagulopathy. 
Diagnosis is confirmed by documenting 
low plasma ∞1-AT levels and determin-
ing ∞1-AT phenotype.
Management is mostly supportive with 
nutritional supplementation. Prognosis 
is related to the severity of the liver dis-
ease. In children with progressive liver 
disease, liver transplantation has shown 
good survival rates of 90% at 1 year and 
80% at 5 years. Prospects for therapy 
include attempts to block ∞1-AT ac-
cumulation in the liver or increase the 
turnover of the accumulated abnormal 
∞ 1-AT protein.16
Progressive Familial Intrahepatic 
Cholestasis (PFIC):
PFIC is a group of genetic disorders that 
show progressive intrahepatic cholesta-
sis. All these disorders have an auto-
somal recessive inheritance.
PFic-1: Is caused by mutation in the 
FIC 1 gene mapped to chromosome 
18q21-22 and is the original Byler dis-
ease described in the descendants of an 
Amish American family. The FIC1 gene 
is expressed in the canalicular mem-
branes. Patients present with episodic 
cholestasis in the first month of life. 
Diarrhea, pancreatitis and deficiency 
of fat-soluble vitamins are seen. Serum 
gamma-glutamyl transpep tidase (GGT) 
levels are normal. Liver biopsy shows 
bile duct paucity. Electron microscopy 
shows granular appearance of bile pres-
ent in the canaliculus. Management is 
mostly supportive. Surgical methods 
like ileal exclusion, partial external bil-
iary diversion have been tried. Cirrho-
sis is seen by end of first decade of life 
and liver transplantation is needed with 
hepatic decompensation and is usually 
needed around the second decade of 
life.
PFic-2: Is caused by a defect in the 
canalicular bile salt excretory pump 
(BSEP) which has a gene locus at chro-
mosome 2q 24. Clinical presentation is 
similar to PFIC 1 except for the absence 
of pancreatitis in this condition. Liver 
biopsy shows more inflammation and 
electron microscopy shows amorphous 
bile. Management is again supportive. 
Prognosis is worse, with patients re-




PFic-3: Is caused by a defect in the 
canalicular phospholipids transporter, 
multiple drug resistant (MDR3) lo-
cated on chromosome 7q21. Clinical 
presentation is similar to PFIC-1 but is 
delayed until early adulthood. There is 
a history of cholestasis of pregnancy in 
the mother. Gamma-glutamyl transpep-
tidase (GGT) is markedly elevated and 
bile analysis shows high bile acid to 
phospholipids ratio. Liver biopsy may 
mimic biliary atresia but the biliary 
tract is patent. Treatment is mostly sup-
portive and prognosis is variable.17
Benign  recurrent  intrahepaticcholesta-
sis (BRIC):
BRIC, or Summerskill-Walshe syn-
drome, has also been mapped to chro-
mosomal region 18q21-22 and to muta-
tions in the FIC 1 gene.
This disease is not rare and manifests 
with recurrent episodes of cholestasis, 
the first attack being possible at any 
age. Cholestasis usually ensues follow-
ing a prodrome with flu-like syndrome 
and may last for several weeks. Labora-
tory tests show elevation of serum bile 
acids, cholesterol, alkaline phosphatase 
and transaminases, but gamma-glutam-
yl transpep tidase (GGT) is only slightly 
elevated. As in PFICl, serum lithocholic 
acid concentrations are substantially el-
evated. Histology is unremarkable, ex-
cept for cholestasis.  
There is a high degree of phenotypic 
variability, but progression of the liver 
disease does not occur.
FICl mutations described in BRIC pa-
tients include a missense mutation and 
a small deletion; unlike PFICl, muta-
tions in BRIC patients are localized in 
less highly conserved regions of the 
FICl gene and likely to have a lower 
impact on structure and function of the 
transporter.18 
alagille Syndrome:                                 
Alagille syndrome is an autosomal 
dominant disorder characterized by 
paucity of the interlobular bile ducts. 
The incidence is reported to be 1 in 
100,000 births. It is also known as Wat-
son-Alagille syndrome, arteriohepatic 
dysplasia, syndromic bile duct paucity 
(SBDP), syndromic intrahepatic biliary 
hypoplasia,  and intrahepatic biliary dys-
genesis. Alagille syndrome is caused by 
mutations in the human Jagged 1 gene 
that has been mapped to chromosome 
20p12. This gene encodes a ligand for 
the Notch signaling pathway.19
Clinically, this syndrome is character-
ized by chronic cholestasis; character-
istic facies with a broad forehead, small 
chin and saddle nose with bulbous tip 
and hypertelorism; skeletal anomalies 
including butterfly vertebrae, curved 
phalanges and short ulna; cardiac 
anomalies most commonly peripheral 
pulmonic stenosis and also including 
tetralogy of Fallot, pulmonary atresia, 
truncus arteriosus and VSD; and ocular 
anomalies like posterior embryotoxon 
and optic nerve drusen. Other findings 
include renal abnormalities like ecto-
pic kidney, small kidneys, multicystic 
kidneys, renal artery stenosis; mental 
retardation and developmental delay; 
growth retardation and pancreatic in-
sufficiency. Infants usually present with 
neonatal cholestasis. It may be difficult 
to differentiate from biliary atresia ini-
tially because in some cases initial liver 
biopsy may show bile duct prolifera-
tion.20
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Management consists of aggressive 
nutritional and fat-soluble vitamin 
support. A major disabling feature for 
many children is pruritus. Pancreatic 
supplementation may be necessary. 
Liver transplantation may also be indi-
cated in some children because of se-
vere impairment of quality of life due 
to pruritus.8 
Disorders of Bile Acid Synthesis        
In 1984, infants with suspected neonatal 
cholestasis were screened for defects in 
bile acid synthesis using the-novel tech-
nique of fast-atom bombardment ion-
ization mass spectrometry (FAB-MS). 
Using this approach, six defects in bile 
acid synthesis have been identified to 
date and account for 2-3% of cholestat-
ic disorders of infancy and childhood.
In neonates, the presentation is similar 
to PFIC. Laboratory tests are variable, 
but all infants have atypical urinary bile 
acids identified by FAB-MS. Treatment 
with oral cholic acid, 250 mg/day, nor-
malized biochemical parameters and re-
versed liver disease in most cases.21
Medical management of cholestasis    
Medical management of cholestasis is 
mostly supportive and does not alter the 
natural course of the disease. It is aimed 
mostly at treating the complications of 
chronic cholestasis like pruritus, mal-
absorption and nutritional deficiencies 
and portal hypertension. 
Table (3) summarizes the drugs used for 
medical management of Cholestasis.
cONclUSiON                                     
Neonatal jaundice lasting greater than 2 
weeks should be explained.  Pale stools 
and dark or yellow urine are evidence 
of liver disease which should be urgent-
ly investigated. The neonatal hepatitis 
syndrome has many causes and a struc-
tured approach to investigation is man-
datory. It should be possible to confirm 
or exclude biliary atresia so that, defini-
tive surgery is not delayed unnecessar-
ily. Infants with cholestasis should have 
vigorous fat-soluble vitamin supple-
mentation including parenteral vitamin 
K if coagulation is abnormal.
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table 3: Symptomatic Treatment of Cholestasis.15
Indication treatment Dose Toxicity /comments
cholestasis : - Phenobarbital  3-10 mg/kg/day - Drowsiness, irritability, 
interference with   vitamin 
D metabolism
- Cholestyramine   250-500 mg/kg/day      - Constipation, acidosis, 
binding of drugs, increased 
steatorrhea 
- Ursodeoxycholic acid     15-20 mg/kg/day         -Transient increase in 
pruritus




Diphenhydramine 5-10 mg/kg/day  - Drowsiness
Hydrochloride hydroxyzine  2-5 mg/kg/day - Drowsiness
- Ultraviolet B light Exposure as needed - Skin burn
- Carbamazepine 20-40 mg/kg/day - Hepatotoxicity, marrow 
suppression, fluid retention
- Rifampin 10 mg/kg/day - Hepatotoxicity, marrow
suppression
- Ursodeoxycholic acid 15-20 mg/kg/day -Transient increase in 
pruritus
Steatorrhea -  Formula containing medium-chain 
triglycerides (e.g., Pregestimil)
120-150 calories/kg/day 
for infants   
- Expensive
- Oil supplement containing medium-chain 
triglycerides
1-2 ml/kg/day - Diarrhea, aspiration
Malabsorption of fat-
soluble vitamins:
- Vitamin A  5,000-25.000  units/day - Hepatitis, pseudotumor
 cerebri, bone lesions
- Vitamin D 2000-6000 units/day - Hypercalcemia, 
hypercalciuria
25-Hydroxycholecalciferol (vitamin D) 3-5 mcg/kg/day - Hypercalcemia, 
hypercalciuria
1,25-Dihydroxycholecalciferol (vitamin D) 0.05-0.2 mcg/kg/day -  Hypercalcemia, 
hypercalciuria
- Vitamin E (oral) 25-200 IU/kg/day - Potentiation of vitamin K 
deficiency
Vitamin E ( TPGS,liqui 15-25 IU/kg/day      - Potentiation of vitamin K 
deficiency
- Vitamin K (oral) 2.5 mg twice/wk to 5 
mg/day
Malabsorption of other 
nutrients:
- Multiple vitamins Up to twice the 
standard dose
- Calcium 25-100 mg/kg/day - Hypercalcemia, 
hypercalciuria
-Phosphorus 25-50 mg/kg/day - Gastrointestinal 
intolerance
- Zinc 1 mg/kg/day - Interference with copper 
and iron absorption
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